Sikander Ailawadhi

7.1k total citations
312 papers, 3.1k citations indexed

About

Sikander Ailawadhi is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sikander Ailawadhi has authored 312 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Hematology, 121 papers in Oncology and 103 papers in Molecular Biology. Recurrent topics in Sikander Ailawadhi's work include Multiple Myeloma Research and Treatments (165 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Protein Degradation and Inhibitors (66 papers). Sikander Ailawadhi is often cited by papers focused on Multiple Myeloma Research and Treatments (165 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Protein Degradation and Inhibitors (66 papers). Sikander Ailawadhi collaborates with scholars based in United States, Germany and France. Sikander Ailawadhi's co-authors include Asher Chanan‐Khan, Taimur Sher, Aneel Paulus, Vivek Roy, Dongyun Yang, Pedram Razavi, Abhisek Swaika, Wendy Cozen, Ryan D. Frank and Pooja Advani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sikander Ailawadhi

288 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sikander Ailawadhi United States 28 1.7k 1.4k 1.1k 620 368 312 3.1k
Sean M. Devlin United States 33 2.1k 1.3× 1.6k 1.1× 1.0k 0.9× 770 1.2× 469 1.3× 269 4.0k
Dianne Pulte United States 31 1.4k 0.8× 1.4k 1.0× 1.0k 0.9× 569 0.9× 553 1.5× 87 3.5k
Peter Mollee Australia 25 841 0.5× 936 0.7× 997 0.9× 444 0.7× 514 1.4× 180 2.5k
Faiz Anwer United States 23 963 0.6× 1.1k 0.8× 782 0.7× 342 0.6× 275 0.7× 328 2.5k
Muneer H. Abidi United States 22 1.5k 0.9× 1.5k 1.1× 977 0.9× 321 0.5× 691 1.9× 92 2.7k
Amir T. Fathi United States 34 2.3k 1.4× 984 0.7× 1.7k 1.6× 703 1.1× 214 0.6× 203 3.8k
Chatchada Karanes United States 30 3.0k 1.8× 1.6k 1.1× 1.0k 0.9× 695 1.1× 368 1.0× 148 4.5k
Joseph Mıkhael United States 37 3.4k 2.0× 2.2k 1.5× 2.9k 2.6× 828 1.3× 417 1.1× 204 4.8k
Ulrich Mey Germany 25 854 0.5× 1.5k 1.0× 653 0.6× 769 1.2× 1.0k 2.8× 68 2.9k
Muzaffar H. Qazilbash United States 34 2.7k 1.6× 1.4k 1.0× 1.2k 1.1× 508 0.8× 383 1.0× 312 3.9k

Countries citing papers authored by Sikander Ailawadhi

Since Specialization
Citations

This map shows the geographic impact of Sikander Ailawadhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sikander Ailawadhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sikander Ailawadhi more than expected).

Fields of papers citing papers by Sikander Ailawadhi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sikander Ailawadhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sikander Ailawadhi. The network helps show where Sikander Ailawadhi may publish in the future.

Co-authorship network of co-authors of Sikander Ailawadhi

This figure shows the co-authorship network connecting the top 25 collaborators of Sikander Ailawadhi. A scholar is included among the top collaborators of Sikander Ailawadhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sikander Ailawadhi. Sikander Ailawadhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mian, Hira, Thomas G Martin, Gregory R. Pond, et al.. (2025). Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia. 39(5). 1252–1255. 1 indexed citations
2.
3.
4.
5.
Ackerman, Benjamin, Ryan W. Gan, Craig S. Meyer, et al.. (2024). Measurement error and bias in real-world oncology endpoints when constructing external control arms. SHILAP Revista de lepidopterología. 4. 1423493–1423493. 1 indexed citations
6.
Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078. 1 indexed citations
7.
Banerjee, Rahul, Rachael Sexton, Aaron S. Rosenberg, et al.. (2024). Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 145(1). 75–84. 3 indexed citations
8.
Ailawadhi, Sikander, Ryan D. Frank, David O. Hodge, et al.. (2024). Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer Journal. 14(1). 86–86. 5 indexed citations
9.
Ailawadhi, Sikander, et al.. (2023). Acute esophageal stricture after bone marrow transplant. Clinical Journal of Gastroenterology. 17(1). 1–5.
10.
Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2023). Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer Journal. 13(1). 47–47. 13 indexed citations
11.
Ailawadhi, Sikander, Masa Lasica, Chengcheng Fu, et al.. (2023). Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 41(16_suppl). 7569–7569.
12.
Mateos, María‐Victoria, Sikander Ailawadhi, Luciano J. Costa, et al.. (2023). Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer Journal. 13(1). 109–109. 10 indexed citations
13.
Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2022). Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma. Transplantation and Cellular Therapy. 28(3). S186–S187. 2 indexed citations
14.
Abeykoon, Jithma P., Iuliana Vaxman, Sanjay V. Patel, et al.. (2022). Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology. 199(1). 95–99. 17 indexed citations
15.
16.
Kumar, Vivek, Sikander Ailawadhi, Aditya Mehta, et al.. (2019). Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal. 9(10). 75–75. 44 indexed citations
17.
Manna, Alak, Salman Ahmed, Sharoon Akhtar, et al.. (2019). Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 25(13). 3974–3985. 31 indexed citations
18.
19.
Niazi, Shehzad K., David O. Hodge, Megha Kureti, et al.. (2017). Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Annals of Hematology. 97(3). 519–528. 19 indexed citations
20.
Ailawadhi, Sikander. (2015). The Changing Face of Multiple Myeloma. 11(10). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sean M. Devlin Breakdown of academic impact, for papers by Dianne Pulte Breakdown of academic impact, for papers by Peter Mollee Breakdown of academic impact, for papers by Faiz Anwer Breakdown of academic impact, for papers by Muneer H. Abidi Breakdown of academic impact, for papers by Amir T. Fathi Breakdown of academic impact, for papers by Chatchada Karanes Breakdown of academic impact, for papers by Joseph Mıkhael Breakdown of academic impact, for papers by Ulrich Mey Breakdown of academic impact, for papers by Muzaffar H. Qazilbash
Rankless by CCL
2026